Solid tumours showing oligoprogression to immune checkpoint inhibitors have the potential for abscopal effects
© 2023. The Author(s)..
PURPOSE: Given the uncertainty surrounding the abscopal effect (AE), it is imperative to identify promising treatment targets. In this study, we aimed to explore the incidence of AE when administering radiotherapy to patients with oligoprogressive solid tumours while they are undergoing treatment with immune checkpoint inhibitors (ICIs).
MATERIALS AND METHODS: In this multicentre prospective observational study, oligoprogressive disease was defined as a < 20% increase in lesions compared to > 2 months before enrolment. We enrolled patients who requested radiotherapy during the ICI rest period between 2020 and 2023. AE was considered present if ≥ 1 non-irradiated lesion decreased by ≥ 30% before the next line of systemic therapy started.
RESULTS: Twelve patients were included in this study; the common primary lesions were in the lungs (four patients) and kidneys (three patients). AEs were observed in six (50%) patients, with a median time to onset of 4 (range 2-9) months after radiotherapy. No significant predictors of AEs were identified. Patients in the AE group had a significantly better 1-year progression-free survival (PFS) rate than those in the non-AE group (p = 0.008). Two patients from the AE group were untreated and progression-free at the last follow-up. Four (33%) patients experienced grade 2 toxicity, with two cases attributed to radiotherapy and the other two to ICI treatment. No grade 3 or higher toxicities were observed in any category.
CONCLUSION: Patients with oligoprogressive disease may be promising targets with potential for AEs. AEs can lead to improved PFS and, in rare cases, to a certain progression-free period without treatment. Irradiating solid tumours in patients with oligoprogressive disease during immune checkpoint inhibitor therapy may be a promising target with the potential for abscopal effects (AEs). AEs can lead to improved progression-free survival and, in rare cases, to a certain progression-free period without treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Japanese journal of radiology - 42(2024), 4 vom: 30. Apr., Seite 424-434 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ito, Makoto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abscopal effect |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11604-023-01516-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365838381 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365838381 | ||
| 003 | DE-627 | ||
| 005 | 20240401232440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11604-023-01516-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM365838381 | ||
| 035 | |a (NLM)38093137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ito, Makoto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Solid tumours showing oligoprogression to immune checkpoint inhibitors have the potential for abscopal effects |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a PURPOSE: Given the uncertainty surrounding the abscopal effect (AE), it is imperative to identify promising treatment targets. In this study, we aimed to explore the incidence of AE when administering radiotherapy to patients with oligoprogressive solid tumours while they are undergoing treatment with immune checkpoint inhibitors (ICIs) | ||
| 520 | |a MATERIALS AND METHODS: In this multicentre prospective observational study, oligoprogressive disease was defined as a < 20% increase in lesions compared to > 2 months before enrolment. We enrolled patients who requested radiotherapy during the ICI rest period between 2020 and 2023. AE was considered present if ≥ 1 non-irradiated lesion decreased by ≥ 30% before the next line of systemic therapy started | ||
| 520 | |a RESULTS: Twelve patients were included in this study; the common primary lesions were in the lungs (four patients) and kidneys (three patients). AEs were observed in six (50%) patients, with a median time to onset of 4 (range 2-9) months after radiotherapy. No significant predictors of AEs were identified. Patients in the AE group had a significantly better 1-year progression-free survival (PFS) rate than those in the non-AE group (p = 0.008). Two patients from the AE group were untreated and progression-free at the last follow-up. Four (33%) patients experienced grade 2 toxicity, with two cases attributed to radiotherapy and the other two to ICI treatment. No grade 3 or higher toxicities were observed in any category | ||
| 520 | |a CONCLUSION: Patients with oligoprogressive disease may be promising targets with potential for AEs. AEs can lead to improved PFS and, in rare cases, to a certain progression-free period without treatment. Irradiating solid tumours in patients with oligoprogressive disease during immune checkpoint inhibitor therapy may be a promising target with the potential for abscopal effects (AEs). AEs can lead to improved progression-free survival and, in rare cases, to a certain progression-free period without treatment | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Abscopal effect | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Oligometastasis | |
| 650 | 4 | |a Oligoprogressive disease | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Abe, Souichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Adachi, Sou |e verfasserin |4 aut | |
| 700 | 1 | |a Oshima, Yukihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Arisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ohashi, Wataru |e verfasserin |4 aut | |
| 700 | 1 | |a Iwata, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kubota, Yasuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Okuda, Takahito |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Kojiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Japanese journal of radiology |d 2009 |g 42(2024), 4 vom: 30. Apr., Seite 424-434 |w (DE-627)NLM187882312 |x 1867-108X |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:4 |g day:30 |g month:04 |g pages:424-434 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11604-023-01516-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 4 |b 30 |c 04 |h 424-434 | ||